Glycotope GmbH, a leading glycobiology company, will present recent advances with its GlycoExpress™ technology of novel human cell lines during the upcoming BIO-Europe in Munich.
With two of its glycooptimized antibodies produced by GlycoExpress™ and already undergoing clinical trials, four European regulatory authorities approved GlycoExpress™ for production of biotherapeutics.
This strongly validates this innovative technology for future development and production of therapeutic proteins. The preclinically observed advantages of glycooptimized biotherapeutics are expected to result in a clear clinical superiority.
All glycooptimized products are produced in Glycotope´s own GMP facility in Heidelberg (Glycotope Biotechnology GmbH).
Source: Glycotope GmbH